AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings
Abstract Studies have shown that the levels of pro-inflammatory adipokines in patients with psoriasis are higher than in general population. The aim of the study was to investigate the influence of 36-month therapy with TNF-α inhibitors (adalimumab, etanercept, infliximab) on the levels of adipokine...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6ae076d2268848daa946d699e5b9a4de |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:6ae076d2268848daa946d699e5b9a4de |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:6ae076d2268848daa946d699e5b9a4de2021-12-02T17:15:17ZAntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings10.1038/s41598-021-88552-62045-2322https://doaj.org/article/6ae076d2268848daa946d699e5b9a4de2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88552-6https://doaj.org/toc/2045-2322Abstract Studies have shown that the levels of pro-inflammatory adipokines in patients with psoriasis are higher than in general population. The aim of the study was to investigate the influence of 36-month therapy with TNF-α inhibitors (adalimumab, etanercept, infliximab) on the levels of adipokines (resistin, adiponectin, leptin) and lipids (TG, cholesterol, LDL, HDL) in 37 psoriasis patients and 30 healthy controls. The mean serum concentrations of adiponectin in patients from adalimumab, etanercept and infliximab group were similar to control group (p > 0.05, 142.71, 164.32, 129.35 and 174.44 μg/ml respectively). Resistin levels were higher in patients (p < 0.05, 4.48, 4.53 and 3.39 ng/ml respectively) than in controls (3.05 ng/ml). Mean leptin concentrations were significantly higher (p < 0.05) in the study group than in subjects without psoriasis (428.61, 523.24, 755.27 and 154.10 pg/ml respectively). A significant decrease in the mean resistin concentration was observed under the influence of biological therapy (p < 0.05). Decrease in serum leptin level was noted in etanercept and infliximab groups (p = 0.001 and p = 0.002 respectively). Improvement in all lipidogram parameters was noted in all examined groups (p < 0.05). Results may prove that biologic therapy affects the systemic inflammation associated with psoriasis and this effect persists with long-term therapy.Irmina Olejniczak-StaruchJoanna NarbuttJustyna CerynMałgorzata SkibińskaIgor BednarskiAnna WoźniackaJoanna SieniawskaMarzena Kraska-GackaMagdalena CiążyńskaJanusz ŚmigielskiMarcin NowetaMichał WaszczykowskiWitold OwczarekAdam ReichAleksandra LesiakNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Irmina Olejniczak-Staruch Joanna Narbutt Justyna Ceryn Małgorzata Skibińska Igor Bednarski Anna Woźniacka Joanna Sieniawska Marzena Kraska-Gacka Magdalena Ciążyńska Janusz Śmigielski Marcin Noweta Michał Waszczykowski Witold Owczarek Adam Reich Aleksandra Lesiak AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings |
description |
Abstract Studies have shown that the levels of pro-inflammatory adipokines in patients with psoriasis are higher than in general population. The aim of the study was to investigate the influence of 36-month therapy with TNF-α inhibitors (adalimumab, etanercept, infliximab) on the levels of adipokines (resistin, adiponectin, leptin) and lipids (TG, cholesterol, LDL, HDL) in 37 psoriasis patients and 30 healthy controls. The mean serum concentrations of adiponectin in patients from adalimumab, etanercept and infliximab group were similar to control group (p > 0.05, 142.71, 164.32, 129.35 and 174.44 μg/ml respectively). Resistin levels were higher in patients (p < 0.05, 4.48, 4.53 and 3.39 ng/ml respectively) than in controls (3.05 ng/ml). Mean leptin concentrations were significantly higher (p < 0.05) in the study group than in subjects without psoriasis (428.61, 523.24, 755.27 and 154.10 pg/ml respectively). A significant decrease in the mean resistin concentration was observed under the influence of biological therapy (p < 0.05). Decrease in serum leptin level was noted in etanercept and infliximab groups (p = 0.001 and p = 0.002 respectively). Improvement in all lipidogram parameters was noted in all examined groups (p < 0.05). Results may prove that biologic therapy affects the systemic inflammation associated with psoriasis and this effect persists with long-term therapy. |
format |
article |
author |
Irmina Olejniczak-Staruch Joanna Narbutt Justyna Ceryn Małgorzata Skibińska Igor Bednarski Anna Woźniacka Joanna Sieniawska Marzena Kraska-Gacka Magdalena Ciążyńska Janusz Śmigielski Marcin Noweta Michał Waszczykowski Witold Owczarek Adam Reich Aleksandra Lesiak |
author_facet |
Irmina Olejniczak-Staruch Joanna Narbutt Justyna Ceryn Małgorzata Skibińska Igor Bednarski Anna Woźniacka Joanna Sieniawska Marzena Kraska-Gacka Magdalena Ciążyńska Janusz Śmigielski Marcin Noweta Michał Waszczykowski Witold Owczarek Adam Reich Aleksandra Lesiak |
author_sort |
Irmina Olejniczak-Staruch |
title |
AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings |
title_short |
AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings |
title_full |
AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings |
title_fullStr |
AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings |
title_full_unstemmed |
AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings |
title_sort |
antitnf-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/6ae076d2268848daa946d699e5b9a4de |
work_keys_str_mv |
AT irminaolejniczakstaruch antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT joannanarbutt antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT justynaceryn antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT małgorzataskibinska antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT igorbednarski antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT annawozniacka antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT joannasieniawska antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT marzenakraskagacka antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT magdalenaciazynska antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT januszsmigielski antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT marcinnoweta antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT michałwaszczykowski antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT witoldowczarek antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT adamreich antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings AT aleksandralesiak antitnfalphatherapynormalizeslevelsoflipidsandadipokinesinpsoriaticpatientsinthereallifesettings |
_version_ |
1718381263927115776 |